Novo Nordisk Q1 adjusted sales fall 4% at CER; 2026 outlook raised to -4% to -12%

Novo Nordisk reported first-quarter reported sales of DKK 96.8 billion, inflated by the USD 4.2 billion 340B reversal. Excluding that item, adjusted sales fell 4% at constant exchange rates and adjusted operating profit fell 6%. The company raised its 2026 outlook to a 4% to 12% decline from 5% to 13%, helped by Wegovy pill sales of DKK 2.26 billion.

• Adjusted sales DKK 70,063 million, down 4% at CER
• Adjusted operating profit DKK 32,858 million, down 6% at CER
• Wegovy injection adjusted sales DKK 18,235 million, up 12% at CER
• Wegovy pill sales DKK 2,256 million
• 2026 outlook raised: adjusted sales and operating profit -4% to -12% at CER (prior -5% to -13%)